MDL-811

Last updated

MDL-811
MDL-811 structure.png
Clinical data
Drug class Sirtuin-6 (SIRT6) activator
Identifiers
  • N-(5-bromo-4-fluoro-2-methylphenyl)-4-[(3,5-dichlorophenyl)sulfonylamino]-2-[[(3R)-3-methylmorpholin-4-yl]methyl]benzenesulfonamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C25H25BrCl2FN3O5S2
Molar mass 681.41 g·mol−1
3D model (JSmol)
  • C[C@@H]1COCCN1CC2=C(C=CC(=C2)NS(=O)(=O)C3=CC(=CC(=C3)Cl)Cl)S(=O)(=O)NC4=CC(=C(C=C4C)F)Br
  • InChI=1S/C25H25BrCl2FN3O5S2/c1-15-7-23(29)22(26)12-24(15)31-39(35,36)25-4-3-20(8-17(25)13-32-5-6-37-14-16(32)2)30-38(33,34)21-10-18(27)9-19(28)11-21/h3-4,7-12,16,30-31H,5-6,13-14H2,1-2H3/t16-/m1/s1
  • Key:ULBHGKXUHYSORN-MRXNPFEDSA-N

MDL-811 is a drug which acts as a sirtuin-6 (SIRT6) activator. It has antiinflammatory effects and shows neuroprotective effects in animal models of stroke and heart attack. [1] [2] [3] [4]

References

  1. Shang J, Zhu Z, Chen Y, Song J, Huang Y, Song K, et al. (2020). "Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D3 in colorectal cancer". Theranostics. 10 (13): 5845–5864. doi:10.7150/thno.44043. PMC   7255010 . PMID   32483423.
  2. He T, Shang J, Gao C, Guan X, Chen Y, Zhu L, et al. (March 2021). "A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/FOXC1 axis". Acta Pharmaceutica Sinica. B. 11 (3): 708–726. doi:10.1016/j.apsb.2020.11.002. PMC   7982432 . PMID   33777677.
  3. Ren SC, Chen X, Gong H, Wang H, Wu C, Li PH, et al. (July 2022). "SIRT6 in Vascular Diseases, from Bench to Bedside". Aging and Disease. 13 (4): 1015–1029. doi:10.14336/AD.2021.1204. PMC   9286919 . PMID   35855341.
  4. Yu XT, Zhao N, Ma YT, Jia JM, Song YT, Liu XY, et al. (September 2025). "Sirtuin 6 mitigates thoracic aortic aneurysm progression via maintenance of mitochondria homeostasis in vascular smooth muscle cells". Acta Pharmacologica Sinica. doi:10.1038/s41401-025-01628-1. PMID   40897853.